TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02408068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone used to suppress endogenous cortisol secretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort: fasted
Description: single dose of 20mg modified release hydrocortisone in the absence of food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release hydrocortisone: fasted
Description: single dose of 20mg immediate release hydrocortisone in the absence of food
Study: NCT04207515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedures of wisdom tooth removal surgery under conscious sedation
Description: The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedures of wisdom tooth removal surgery under local anesthesia
Description: The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
Study: NCT02408068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort: fed
Description: single dose of 20mg modified release hydrocortisone in the presence of food
Study: NCT03929783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CEM
Study: NCT04733872

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects drank 50 ml , 1 bottle a day for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable and Berry Drink
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study: NCT01328197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System
Description: Stent-graft implant
Study: NCT02059018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Study: NCT04600687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
Study: NCT03222219

Intervention type: PROCEDURE
Intervention: dental implant insertion
Description: the registration of the torque values is discriminant for the group assignment after dental implant insertion
Study: NCT02059018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
Study: NCT03222219

Intervention type: PROCEDURE
Intervention: dental implant insertion
Description: the registration of the torque values is discriminant for the group assignment after dental implant insertion

Intervention type: PROCEDURE
Intervention: dental implant insertion
Description: the registration of the torque values is discriminant for the group assignment after dental implant insertion
Study: NCT04263194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Placebo intervention will consist in the same procedure but using a sham rTMS coil.
Study: NCT03030898

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: respiratory variation of the right internal jugular vein
Description: respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
Study: NCT04365686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol as induction agent
Description: Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
Study: NCT02059018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor + Nitroglycerin
Description: Combination of COX-inhibitor and nitroglycerin interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-inhibitor + Nitroglycerin
Description: Combination of COX-inhibitor and nitroglycerin interventions.
Study: NCT00462618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogntive behavioral therapy
Study: NCT00461422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: sc injection of Ganirelix 0.25 mg per day
Study: NCT00510484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 24000 unit Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT02221947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1
Description: 25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
Study: NCT01325181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin
Description: a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
Study: NCT03920176

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography coronary angiography
Description: CTCA \>64 detector row scanner

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ASSIGN Score
Description: ASSIGN Cardiovascular Risk Score
Study: NCT00535691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Twice daily, 14 days treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Once daily, 14 days treatment.
Study: NCT01136863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00723671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT00886106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
Study: NCT03527316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: 125 mg MDMA per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: 125 mg MDMA per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs.
Study: NCT00000936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine
Description: Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cyclosporine
Description: Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
Study: NCT02221947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single dose via intravenous infusion over 1 hour.
Study: NCT03736733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months.
Study: NCT01917890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)
Study: NCT04365686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol as induction agent
Description: Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
Study: NCT02056444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT01917890

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)
Study: NCT03736733

Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
Study: NCT03944421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red and Processed Meat
Description: Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
Study: NCT02056444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT01016067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE/MASTERGRAFT
Description: INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Study: NCT03944421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quorn
Description: Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
Study: NCT03757325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: DNL747
Study: NCT03772340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT01661309

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive lozenge
Description: Manufactured to mimic 1mg methylcobalamin lozenge

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inactive lozenge
Description: Manufactured to mimic 1mg methylcobalamin lozenge

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Methylcobalamin
Description: Aimed at reducing plasma tHcy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Description: Aimed at reducing plasma tHcy.
Study: NCT03419000

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
Study: NCT04390789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical Single visit Retreatment
Description: Non-surgical endodontic retreatment will be carried out in single visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi visit Retreatment with calcium hydroxide dressing
Description: In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
Study: NCT00606853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards valued $1-$100 for abstinence or treatment attendance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards valued $1-$100 for abstinence or treatment attendance
Study: NCT00000936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cyclosporine
Description: Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
Study: NCT03059004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeMPO Home Exercise Program
Description: This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeMPO Home Exercise Program
Description: This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
Study: NCT00606853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards valued $1-$100 for abstinence or treatment attendance
Study: NCT03980626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
Study: NCT03059004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeMPO Home Exercise Program
Description: This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeMPO Home Exercise Program
Description: This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS Messages
Description: The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
Study: NCT01631292

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU Vitamin D3
Description: Once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2000 IU Vitamin D3
Description: Once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU Vitamin D3
Description: Once daily
Study: NCT03733457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Stepped-care
Description: Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
Study: NCT01353755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grass pollen specific immunotherapy
Description: * Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placabo
Description: Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
Study: NCT01268943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study: NCT01016067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft bone
Description: Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Study: NCT03199794

Intervention type: BIOLOGICAL
Intervention: OBIZUR
Description: Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
Study: NCT01268943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study: NCT01184456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GanedenBC30, GBI-30, PTA-6086
Description: 1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for 90 days.
Study: NCT01758211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI Navigation AVM resection
Description: intraoperative fMRI navigation guided resection in AVM patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional resection
Description: conventional resection in AVM patients
Study: NCT04155658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Toothpaste containing 1450ppm SMFP
Description: Experimental Toothpaste containing 1450ppm SMFP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 1450ppm SMFP
Description: Toothpaste containing 1450ppm SMFP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste with no fluoride
Description: Toothpaste with no fluoride
Study: NCT01266889

Intervention type: DEVICE
Intervention: device:INVOS 5100
Description: Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
Study: NCT02301754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INVAC-1
Description: intradermal injection combined with electroporation
Study: NCT02226978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Study: NCT01825330

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS and cognitive stimulation
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Study: NCT04683406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 600 mg
Description: 3 X 200-mg tablet taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir2 X 75-mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir2 X 75-mg